GET TO KNOW THE SAIM COALITION
AND OUR MISSION
Thanks to innovative new medicines, diseases that were once fatal or debilitating are now being treated and managed as chronic conditions. Given recent trends in benefit design for health insurance plans, however, these breakthrough treatments may be financially out of reach for many patients. The State Access to Innovative Medicines (SAIM) Coalition’s mission is to facilitate collaboration between patient advocacy, health care
provider, and life sciences organizations to advance state policies that improve patient access to innovative medicines. This includes developing policy positions and resources that underpin these strategies and partnering with non-member organizations at the state level to drive successful legislative, regulatory, and grassroots strategies.
SAIM Coalition members work together to help ensure that patients across the nation have access to the treatments that they need.
The SAIM Coalition is comprised of patient advocacy organizations, healthcare provider societies and biopharmaceutical companies. All SAIM Coalition members are national organizations with a presence at the state level who have a position on the coalition’s core issues and are required to make annual financial contributions to support the coalition. SAIM is led by two co-chair patient and provider organizations that are elected by the membership and serve for a two-year term. The coalition maintains a majority membership of patient and provider-led organizations as required under its bylaws.
The SAIM Coalition is a 501(c)(4) nonprofit incorporated in the District of Columbia. All members pay annual dues and have equal status with each member having one vote regarding coalition priorities and direction. Click here to view our most recent Form 990.